UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

NPJ breast cancer, 2022-08, Vol.8 (1), p.98-10, Article 98

2022

Volltextzugriff (PDF)

5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5208-5212

2009

Volltextzugriff (PDF)

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Journal of clinical oncology, 2021-08, Vol.39 (22), p.2474-2485

2021

Volltextzugriff (PDF)

Impact of Cancer‐Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition

The oncologist (Dayton, Ohio), 2000-10, Vol.5 (5), p.353-360

2000

Volltextzugriff (PDF)

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

NPJ breast cancer, 2024-06, Vol.10 (1), p.41-1, Article 41

2024

Volltextzugriff (PDF)

Cancer‐Related Fatigue: Guidelines for Evaluation and Management

The oncologist (Dayton, Ohio), 1999-02, Vol.4 (1), p.1-10

1999

Volltextzugriff (PDF)

Chemotherapy-Induced Anemia in Adults: Incidence and Treatment

JNCI : Journal of the National Cancer Institute, 1999-10, Vol.91 (19), p.1616-1634

1999

Volltextzugriff (PDF)

LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)

European journal of cancer (1990), 2009-07, Vol.45 (10), p.1807-1814

2009

Volltextzugriff (PDF)

Erythropoietin Crosses the Blood-Brain Barrier to Protect against Experimental Brain Injury

Proceedings of the National Academy of Sciences - PNAS, 2000-09, Vol.97 (19), p.10526-10531

2000

Volltextzugriff (PDF)

The Efficacy and Safety of the Fentanyl Iontophoretic Transdermal System (IONSYS®) in the Geriatric Population: Results of a Meta-Analysis of Phase III and IIIb Trials

Drugs & aging, 2016-12, Vol.33 (12), p.901-912

2016

Volltextzugriff (PDF)

Fentanyl Iontophoretic Transdermal System (IONSYS®) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices

Advances in therapy, 2016-09, Vol.33 (9), p.1649-1659

2016

Volltextzugriff (PDF)

13-cis-retinoic acid in the treatment of oral leukoplakia

The New England journal of medicine, 1986-12, Vol.315 (24), p.1501

1986

Volltextzugriff (PDF)

High Body Mass Index and Use of Fentanyl Iontophoretic Transdermal System in Postoperative Pain Management: Results of a Pooled Analysis of Six Phase 3/3B Trials

Pain and therapy, 2017-06, Vol.6 (1), p.29-43

2017

Volltextzugriff (PDF)

Use of Fentanyl Iontophoretic Transdermal System (ITS) (IONSYS®) in the Management of Patients with Acute Postoperative Pain: A Case Series

Pain and therapy, 2016-12, Vol.5 (2), p.237-248

2016

Volltextzugriff (PDF)

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541

2021

Volltextzugriff (PDF)

Neuroprotective properties of epoetin alfa

Nephrology, dialysis, transplantation, 2002-01, Vol.17 (suppl-1), p.8-12

2002

Volltextzugriff (PDF)

Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)

The New England journal of medicine, 1991-05, Vol.324 (20), p.1385-1393

1991

Volltextzugriff (PDF)

Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 1990-09, Vol.323 (12), p.795-801

1990

Volltextzugriff (PDF)

The use of epoetin alfa in chemotherapy patients: A consistent profile of efficacy and safety

Seminars in oncology, 2002-06, Vol.29 (3), p.81-87

Itri, Loretta M.

2002

Volltextzugriff (PDF)

Managing cancer‐related anaemia with epoetin alfa

Nephrology, dialysis, transplantation, 2002-01, Vol.17 (suppl-1), p.73-77

ITRI, Loretta M

2002

Volltextzugriff (PDF)

Abstract PS11-09: Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS11-09-PS11-09

2021

Volltextzugriff (PDF)

Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS3-06-GS3-06

2021

Volltextzugriff (PDF)

Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD13-07-PD13-07

2021

Volltextzugriff (PDF)

Cancer‐related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy

Nephrology, dialysis, transplantation, 2001-12, Vol.16 (12), p.2289-2293

ITRI, Loretta M

2001

Volltextzugriff (PDF)

Abstract LB288: Biomarker analysis from AMPECT correlating response to nab -sirolimus with TSC1 and TSC2 inactivating alterations

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB288-LB288

2023

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(53)
Buchkapitel
(1)

Sprache

Englisch
(54)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Impact of Cancer‐Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Cancer‐Related Fatigue: Guidelines for Evaluation and Management

Chemotherapy-Induced Anemia in Adults: Incidence and Treatment

LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)

Erythropoietin Crosses the Blood-Brain Barrier to Protect against Experimental Brain Injury

The Efficacy and Safety of the Fentanyl Iontophoretic Transdermal System (IONSYS®) in the Geriatric Population: Results of a Meta-Analysis of Phase III and IIIb Trials

Fentanyl Iontophoretic Transdermal System (IONSYS®) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices

13-cis-retinoic acid in the treatment of oral leukoplakia

High Body Mass Index and Use of Fentanyl Iontophoretic Transdermal System in Postoperative Pain Management: Results of a Pooled Analysis of Six Phase 3/3B Trials

Use of Fentanyl Iontophoretic Transdermal System (ITS) (IONSYS®) in the Management of Patients with Acute Postoperative Pain: A Case Series

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Neuroprotective properties of epoetin alfa

Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)

Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck

The use of epoetin alfa in chemotherapy patients: A consistent profile of efficacy and safety

Managing cancer‐related anaemia with epoetin alfa

Abstract PS11-09: Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer

Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer

Cancer‐related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy

Abstract LB288: Biomarker analysis from AMPECT correlating response to nab -sirolimus with TSC1 and TSC2 inactivating alterations

Suchergebnisse filtern